SRPT SECURITIES NEWS: Did Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Commit Securities Fraud? Contact BFA Law by August 25 Class Action Deadline
If you invested in Sarepta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action.
Investors have until August 25, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Sarepta securities. The case is pending in the U.S. District Court for the Southern District of New York and is captioned Dolgicer v. Sarepta Therapeutics, Inc., et al. , No. 25-cv-05317.
Why Was Sarepta Sued for Securities Fraud?
Sarepta is a biopharmaceutical company focused on developing treatments for rare diseases. Sarepta's most important product is Elevidys, a therapy for the treatment of Duchenne muscular dystrophy. As alleged, Sarepta repeatedly touted the safety profile of Elevidys and told investors that the benefits of the treatment outweighed its risks.
In truth, Elevidys causes fatal acute liver failure in some patients.
The Stock Declines as the Truth Is Revealed
On March 18, 2025, Sarepta announced that a patient that had been treated with Elevidys died after suffering acute liver failure. On this news, the price of Sarepta stock fell $27.81 per share, or over 27%, from $101.35 per share on March 17, 2025, to $73.54 per share on March 18, 2025. Nevertheless, on the same day, Sarepta assured investors that 'the benefit-risk of ELEVIDYS remains positive.'
Next, on June 15, 2025, Sarepta announced that a second patient treated with Elevidys had died from acute liver failure and that it was suspending certain shipments of Elevidys and paused dosing in an ongoing clinical trial of the treatment. On this news, the price of Sarepta stock fell $15.24 per share, or more than 42%, from $36.18 per share on June 13, 2025, to $20.94 per share on June 16, 2025.
Finally, on July 17, 2025, Sarepta revealed that a third patient treated with one of Sarepta's investigational treatments related to Elevidys had died from acute liver failure in June 2025. On this news, the price of Sarepta stock fell more than 40% on July 18, 2025.
Click here for more information: https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action.
What Can You Do?
If you invested in Sarepta you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
https://www.bfalaw.com/cases-investigations/sarepta-therapeutics-inc-class-action
Or contact:Ross Shikowitz
[email protected]
212-789-3619
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Red Rock Resorts (RRR) Reports Q2: Everything You Need To Know Ahead Of Earnings
Casino resort and entertainment company Red Rock Resorts (NASDAQ:RRR) will be announcing earnings results this Tuesday after the bell. Here's what investors should know. Red Rock Resorts beat analysts' revenue expectations by 0.6% last quarter, reporting revenues of $497.9 million, up 1.8% year on year. It was a satisfactory quarter for the company, with an impressive beat of analysts' EPS estimates but a miss of analysts' Casino revenue estimates. Is Red Rock Resorts a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Red Rock Resorts's revenue to be flat year on year at $485.4 million, slowing from the 16.9% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.41 per share. Heading into earnings, analysts covering the company have grown increasingly bearish with revenue estimates seeing 4 downward revisions over the last 30 days (we track 10 analysts). Red Rock Resorts has missed Wall Street's revenue estimates three times over the last two years. Looking at Red Rock Resorts's peers in the consumer discretionary segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Monarch delivered year-on-year revenue growth of 6.8%, beating analysts' expectations by 5.4%, and Boyd Gaming reported revenues up 6.9%, topping estimates by 5.4%. Monarch traded up 20.4% following the results while Boyd Gaming was also up 4.1%. Read our full analysis of Monarch's results here and Boyd Gaming's results here. There has been positive sentiment among investors in the consumer discretionary segment, with share prices up 10.3% on average over the last month. Red Rock Resorts is up 8.9% during the same time and is heading into earnings with an average analyst price target of $57.77 (compared to the current share price of $56.64). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 minutes ago
- Yahoo
The Cheesecake Factory (CAKE) Reports Earnings Tomorrow: What To Expect
Restaurant company Cheesecake Factory (NASDAQ:CAKE) will be announcing earnings results this Tuesday after market close. Here's what to expect. The Cheesecake Factory met analysts' revenue expectations last quarter, reporting revenues of $927.2 million, up 4% year on year. It was a strong quarter for the company, with an impressive beat of analysts' EBITDA estimates and a decent beat of analysts' EPS estimates. Is The Cheesecake Factory a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting The Cheesecake Factory's revenue to grow 4.9% year on year to $948.3 million, in line with the 4.4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.06 per share. Heading into earnings, analysts covering the company have grown increasingly bearish with revenue estimates seeing 8 downward revisions over the last 30 days (we track 15 analysts). The Cheesecake Factory has missed Wall Street's revenue estimates four times over the last two years. Looking at The Cheesecake Factory's peers in the restaurants segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Kura Sushi delivered year-on-year revenue growth of 17.3%, beating analysts' expectations by 2.5%, and Darden reported revenues up 10.6%, in line with consensus estimates. Kura Sushi traded down 11.8% following the results while Darden's stock price was unchanged. Read our full analysis of Kura Sushi's results here and Darden's results here. There has been positive sentiment among investors in the restaurants segment, with share prices up 2.7% on average over the last month. The Cheesecake Factory is up 6% during the same time and is heading into earnings with an average analyst price target of $62.41 (compared to the current share price of $66.39). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
5 minutes ago
- Yahoo
Earnings To Watch: NMI Holdings (NMIH) Reports Q2 Results Tomorrow
Mortgage insurance provider NMI Holdings (NASDAQ:NMIH) will be reporting results this Tuesday after the bell. Here's what you need to know. NMI Holdings beat analysts' revenue expectations by 3% last quarter, reporting revenues of $173.2 million, up 10.9% year on year. It was an exceptional quarter for the company, with a solid beat of analysts' net premiums earned estimates and a solid beat of analysts' EPS estimates. Is NMI Holdings a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting NMI Holdings's revenue to grow 7.6% year on year to $174.4 million, slowing from the 13.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.19 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. NMI Holdings has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 1.2% on average. Looking at NMI Holdings's peers in the property & casualty insurance segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Stewart Information Services delivered year-on-year revenue growth of 20.1%, beating analysts' expectations by 9.2%, and First American Financial reported revenues up 14.2%, topping estimates by 4.9%. Stewart Information Services traded up 10.3% following the results while First American Financial was also up 3.5%. Read our full analysis of Stewart Information Services's results here and First American Financial's results here. Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the property & casualty insurance stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.5% on average over the last month. NMI Holdings is down 9.9% during the same time and is heading into earnings with an average analyst price target of $43.71 (compared to the current share price of $38). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
